COMMUNIQUÉS West-GlobeNewswire

Transactions in connection with share buy-back program
11/08/2026
Company announcement no. 30 - 26 11 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Exor and Philips Extend Long-term Relationship Agreement
11/08/2026
August 11, 2026 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. today announced that they have agreed to update their long-term relationship [...]
Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed
11/08/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed [...]
Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
11/08/2026
Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence” Lower schedule expected to enhance patient access in the US Allschwil [...]
NORTH Performance Launches Globally with Pre-Sales Site and Founding Athlete Co-Owner Roster
11/08/2026
Next-generation all-in-one performance supplement brand, built on a radical athlete co-ownership model, opens pre-sales ahead of September 2026 product launch DOVER, Del., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NORTH [...]
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
11/08/2026
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
Solésence Reschedules Second Quarter 2026 Conference Call to August 19
11/08/2026
ROMEOVILLE, Ill., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company has [...]
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
10/08/2026
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the [...]
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
10/08/2026
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion [...]
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
10/08/2026
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company [...]
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
10/08/2026
One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence [...]
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
10/08/2026
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for- [...]
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
10/08/2026
Discussions with FDA advance toward expected marketing authorization for GraftAssureDx FDA completes current portion of substantive review in a timely manner Favorable Medicare reimbursement policy issued in July [...]
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
10/08/2026
– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long - term safety and tolerability profile remained consistent with [...]
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
10/08/2026
Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026. "Our [...]
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
10/08/2026
FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
TELA Bio Reports Second Quarter 2026 Financial Results
10/08/2026
MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08/2026
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, [...]
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
10/08/2026
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval [...]

Pages